Agilent (A) Minimally Impacted by Helium Price Hikes

FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies

Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff

FierceBiotechTraws defers midphase flu study after negative regulatory review

Endpoints NewsSix leaders working on LGBTQ+ inclusion in biopharma

BioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitors

BioWorldCaregen reports new GLP-1R agonists

BioWorldIteos Belgium discloses new PTPN1/2 inhibitors

BioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIV

BioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent

LabiotechNew names, new narratives: Why biotechs decide to rebrand

PharmaVoiceThe biotech market is rebounding. So where are the executive jobs?

FierceBiotechSoligenix axes lymphoma program after phase 3 setback, mulls M&A options